Exploring the inter-subject variability in the relationship between glucose monitoring metrics and glycated hemoglobin for pediatric patients with type 1 diabetes.
HbA1c
children
continuous glucose monitoring
regression analysis
time in range
type 1 diabetes
Journal
Journal of pediatric endocrinology & metabolism : JPEM
ISSN: 2191-0251
Titre abrégé: J Pediatr Endocrinol Metab
Pays: Germany
ID NLM: 9508900
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
21
12
2020
accepted:
01
03
2021
pubmed:
7
4
2021
medline:
24
11
2021
entrez:
6
4
2021
Statut:
epublish
Résumé
Despite the widespread diffusion of continuous glucose monitoring (CGM) systems, which includes both real-time CGM (rtCGM) and intermittently scanned CGM (isCGM), an effective application of CGM technology in clinical practice is still limited. The study aimed to investigate the relationship between isCGM-derived glycemic metrics and glycated hemoglobin (HbA1c), identifying overall CGM targets and exploring the inter-subject variability. A group of 27 children and adolescents with type 1 diabetes under multiple daily injection insulin-therapy was enrolled. All participants used the isCGM Abbott's FreeStyle Libre system on average for eight months, and clinical data were collected from the Advanced Intelligent Distant-Glucose Monitoring platform. Starting from each HbA1c exam date, windows of past 30, 60, and 90 days were considered to compute several CGM metrics. The relationships between HbA1c and each metric were explored through linear mixed models, adopting an HbA1c target of 7%. Time in Range and Time in Target Range show a negative relationship with HbA1c (R This study confirms the relationship between several CGM metrics and HbA1c; it also highlights the importance of an individualized interpretation of the CGM data.
Identifiants
pubmed: 33823102
pii: jpem-2020-0725
doi: 10.1515/jpem-2020-0725
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
619-625Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Patterson, CC, Karuranga, S, Salpea, P, Saeedi, P, Dahlquist, G, Soltesz, G, et al.. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 2019;157:107842.
Nevo-Shenker, M, Phillip, M, Nimri, R, Shalitin, S. Type 1 diabetes mellitus management in young children: implementation of current technologies. Pediatr Res 2020;87:624–9.
Neu, A, Bürger-Büsing, J, Danne, T, Dost, A, Holder, M, Holl, RW, et al.. Diagnosis, therapy and follow-up of diabetes mellitus in children and adolescents. Exp Clin Endocrinol Diabetes 2019;127:341–52.
Braffett, BH, Gubitosi-Klug, RA, Albers, JW, Feldman, EL, Martin, CL, White, NH, et al.. Risk factors for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes 2020;69:1000–10.
Bebu, I, Schade, D, Braffett, B, Kosiborod, M, Lopes-Virella, M, Soliman, EZ, et al.. Risk factors for first and subsequent CVD Events in type 1 diabetes: the DCCT/EDIC study. Diabetes Care 2020;43:867–74.
Wright, LA-C, Hirsch, IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Therapeut 2017;19:S–16.
Bruttomesso, D, Laviola, L, Avogaro, A, Bonora, E, Del Prato, S, Frontoni, S, et al.. The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: a consensus view of Italian diabetes experts using the Delphi method. Nutr Metab Cardiovasc Dis 2019;29:421–31.
Danne, T, Nimri, R, Battelino, T, Bergenstal, RM, Close, KL, DeVries, JH, et al.. International consensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631–40.
Marks, BE, Wolfsdorf, JI. Monitoring of pediatric type 1 diabetes. Front Endocrinol 2020;11:128.
Beck, RW, Bergenstal, RM, Cheng, P, Kollman, C, Carlson, AL, Johnson, ML, et al.. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol 2019;13:614–26.
Battelino, T, Danne, T, Bergenstal, RM, Amiel, SA, Beck, R, Biester, T, et al.. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–603.
Salvi, E, Bosoni, P, Tibollo, V, Kruijver, L, Calcaterra, V, Sacchi, L, et al.. Patient-generated Health data integration and advanced analytics for diabetes management: the AID-GM platform. Sensors 2020;20:128.
FreeStyle. LibreFreeStyle Libre 14-day system|glucose sensor & reader; 2020. Available from: https://www.freestylelibre.us/.
Adolfsson, P, Parkin, CG, Thomas, A, Krinelke, LG. Selecting the appropriate continuous glucose monitoring system – a practical approach. Eur Endocrinol 2018;14:24–9.
Edge, J, Acerini, C, Campbell, F, Hamilton-Shield, J, Moudiotis, C, Rahman, S, et al.. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child 2017;102:543–9.
DiMeglio, LA, Acerini, CL, Codner, E, Craig, ME, Hofer, SE, Pillay, K, et al.. ISPAD Clinical Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 2018;19:105–14.
Laird, NM, Ware, JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–74.
Nakagawa, S, Schielzeth, H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol 2013;4:133–42.
R Documentation. Multi-Model Inference package (version 1.43.17); 2020. Available from: https://www.rdocumentation.org/packages/MuMIn/versions/1.43.17.
R Documentation. Linear Mixed-Effects Models function; 2020. Available from: https://www.rdocumentation.org/packages/nlme/versions/3.1-148/topics/lme.
Piona, C, Marigliano, M, Mozzillo, E, Franzese, A, Zanfardino, A, Iafusco, D, et al.. Long‐term glycemic control and glucose variability assessed with continuous glucose monitoring in a pediatric population with type 1 diabetes: determination of optimal sampling duration. Pediatric Diabetes 2020;21:1485–92.
Vigersky, RA, McMahon, C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Therapeut 2018;21:81–5.
Petersson, J, Åkesson, K, Sundberg, F, Särnblad, S. Translating glycated hemoglobin A1c into time spent in glucose target range: a multicenter study. Pediatr Diabetes 2019;20:339–44.
Bergenstal, RM, Beck, RW, Close, KL, Grunberger, G, Sacks, DB, Kowalski, A, et al.. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 2018;41:2275–80.
Group, JDRFCGMS. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the juvenile diabetes research foundation continuous glucose monitoring randomized trial. Diabetes Care 2011;34:540–4.
Hirsch, IB, Welsh, JB, Calhoun, P, Puhr, S, Walker, TC, Price, DA. Associations between HbA1c and continuous glucose monitoring-derived glycaemic variables. Diabet Med 2019;36:1637–42.